CLINICAL TRIALS PROFILE FOR PITOCIN

All Clinical Trials for PITOCIN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00263796 ↗	An fMRI Study of the Effect of Intravenous Oxytocin vs. Placebo on Response Inhibition and Face Processing in Autism	Completed	Anagnostou, Evdokia, M.D.	Phase 1	2006-03-01	To study the effect of oxytocin on face processing and response inhibition in autistic adults by fMRI.
NCT00308711 ↗	Safety/Efficacy Study Comparing the Misoprostol Vaginal Insert to Cervidil for Cervical Ripening and Induction of Labor	Completed	Ferring Pharmaceuticals	Phase 3	2006-04-01	The purpose of this study is to determine whether the misoprostol vaginal insert (50 mcg and 100 mcg) can safely and effectively speed time to vaginal delivery compared to Cervidil (R) in women who need to have cervical ripneing and induction of labor.
NCT00663039 ↗	Effects of Oxytocin Nasal Spray on Social Affiliation	Completed	National Institute of Mental Health (NIMH)	Phase 2	2009-10-01	Schizophrenia is a complex and heritable disorder that encompasses several clinical symptom domains and functional impairments. Existing treatments of schizophrenia, although effective against positive symptoms, fail to benefit negative symptoms, the focus of the current protocol. One of the strategies of novel drug development depends on identifying heritable physiological deficits that mark the disease liability and are thought to occur along the causal pathway of negative symptoms. These heritable physiological deficits are often found in the biological relatives of schizophrenia proband; particularly those who have schizophrenia related personality styles [defined by schizophrenia spectrum personalities (SSP) in the diagnostic system], even though they do not have the full-blown illness. The current protocol will pilot a strategy of targeting biomarkers of negative symptoms using intranasal oxytocin in relatives of schizophrenia patients. The drug probe studies in such non-clinical sample have several advantages including the absence of other drug treatment that may modulate the response, and the lack of generalized deficits causing problems with task comprehension/engagement that may mute the therapeutic signal. In addition, finding of efficacy of the experimental drug on the target physiological deficit and the associated symptoms has clinical implications on its own rights. This is because about 25% of subjects with schizophrenia spectrum personality disorders experience serious functional impairments. Oxytocin is an extensively used drug, which is well tolerated with few serious side effects. Several lines of evidence suggest its putative role in the treatment of negatives symptoms, particularly a lack of social drive and related symptoms.
NCT00663039 ↗	Effects of Oxytocin Nasal Spray on Social Affiliation	Completed	University of Maryland	Phase 2	2009-10-01	Schizophrenia is a complex and heritable disorder that encompasses several clinical symptom domains and functional impairments. Existing treatments of schizophrenia, although effective against positive symptoms, fail to benefit negative symptoms, the focus of the current protocol. One of the strategies of novel drug development depends on identifying heritable physiological deficits that mark the disease liability and are thought to occur along the causal pathway of negative symptoms. These heritable physiological deficits are often found in the biological relatives of schizophrenia proband; particularly those who have schizophrenia related personality styles [defined by schizophrenia spectrum personalities (SSP) in the diagnostic system], even though they do not have the full-blown illness. The current protocol will pilot a strategy of targeting biomarkers of negative symptoms using intranasal oxytocin in relatives of schizophrenia patients. The drug probe studies in such non-clinical sample have several advantages including the absence of other drug treatment that may modulate the response, and the lack of generalized deficits causing problems with task comprehension/engagement that may mute the therapeutic signal. In addition, finding of efficacy of the experimental drug on the target physiological deficit and the associated symptoms has clinical implications on its own rights. This is because about 25% of subjects with schizophrenia spectrum personality disorders experience serious functional impairments. Oxytocin is an extensively used drug, which is well tolerated with few serious side effects. Several lines of evidence suggest its putative role in the treatment of negatives symptoms, particularly a lack of social drive and related symptoms.
NCT00663039 ↗	Effects of Oxytocin Nasal Spray on Social Affiliation	Completed	University of Maryland, Baltimore	Phase 2	2009-10-01	Schizophrenia is a complex and heritable disorder that encompasses several clinical symptom domains and functional impairments. Existing treatments of schizophrenia, although effective against positive symptoms, fail to benefit negative symptoms, the focus of the current protocol. One of the strategies of novel drug development depends on identifying heritable physiological deficits that mark the disease liability and are thought to occur along the causal pathway of negative symptoms. These heritable physiological deficits are often found in the biological relatives of schizophrenia proband; particularly those who have schizophrenia related personality styles [defined by schizophrenia spectrum personalities (SSP) in the diagnostic system], even though they do not have the full-blown illness. The current protocol will pilot a strategy of targeting biomarkers of negative symptoms using intranasal oxytocin in relatives of schizophrenia patients. The drug probe studies in such non-clinical sample have several advantages including the absence of other drug treatment that may modulate the response, and the lack of generalized deficits causing problems with task comprehension/engagement that may mute the therapeutic signal. In addition, finding of efficacy of the experimental drug on the target physiological deficit and the associated symptoms has clinical implications on its own rights. This is because about 25% of subjects with schizophrenia spectrum personality disorders experience serious functional impairments. Oxytocin is an extensively used drug, which is well tolerated with few serious side effects. Several lines of evidence suggest its putative role in the treatment of negatives symptoms, particularly a lack of social drive and related symptoms.
NCT00684606 ↗	Transcervical Foley Catheter With or Without Oxytocin for Induction of Labor	Unknown status	Sheba Medical Center	N/A	2008-05-01	The purpose of the present study is to evaluate the possible benefit of concurrent IV Oxytocin infusion with trans cervical Foley catheter for pre-induction cervical ripening.
NCT00784797 ↗	Misopristol Versus Pitocin for Second Trimester Abortion	Completed	Hadassah Medical Organization	Phase 4	2009-01-01	Second trimester abortion can be done surgically or medically. Medical abortion with mifepristone and misopristol is one of the common protocol, but misopristol have high rate side effect. The investigators recent study proved the efficacy of pitocin after mifepristone in second trimester abortion with minimal side effects. Working hypothesis and aims: To compare misopristol and pitocin after mifepristone preparation in second trimester in seccess rate, interval to abortion, side effects and patient satisfaction.

Clinical Trial Conditions for PITOCIN

Condition Name

Condition Name for PITOCIN
Intervention	Trials
Postpartum Hemorrhage	22
Osteoarthritis, Knee	7
Pregnancy	7
Induction of Labor	5

Condition MeSH

Condition MeSH for PITOCIN
Intervention	Trials
Hemorrhage	28
Postpartum Hemorrhage	24
Rupture	7
Osteoarthritis, Knee	7

Clinical Trial Locations for PITOCIN

Trials by Country

Trials by Country for PITOCIN
Location	Trials
United States	88
Canada	19
Israel	9
India	2
Malaysia	2

Trials by US State

Trials by US State for PITOCIN
Location	Trials
North Carolina	14
South Carolina	11
California	8
New York	7
Illinois	4

Clinical Trial Progress for PITOCIN

Clinical Trial Phase

Clinical Trial Phase for PITOCIN
Clinical Trial Phase	Trials
PHASE3	1
Phase 4	20
Phase 3	6

Clinical Trial Status

Clinical Trial Status for PITOCIN
Clinical Trial Phase	Trials
Completed	50
Recruiting	22
Unknown status	15

Clinical Trial Sponsors for PITOCIN

Sponsor Name

Sponsor Name for PITOCIN
Sponsor	Trials
Samuel Lunenfeld Research Institute, Mount Sinai Hospital	16
Wake Forest University Health Sciences	13
Medical University of South Carolina	10

Sponsor Type

Sponsor Type for PITOCIN
Sponsor	Trials
Other	120
NIH	8
U.S. Fed	6

PITOCIN Market Analysis and Financial Projection

Last updated: April 28, 2026

Pitocin (oxytocin): Clinical Trials Update, Market Analysis, and 2025-2035 Projection

What is Pitocin and how is it used clinically?

Pitocin is the brand name for oxytocin (human uterotonic). It is used to induce or augment labor, and it is widely available as an injectable product in obstetrics. In practice, Pitocin competes primarily as an administered obstetric uterotonic rather than a molecule with meaningful differentiation across branded products.

Commercial positioning is shaped by:

• Universal clinical need (labor induction and augmentation)
• Physician-administered hospital use
• Generic penetration for oxytocin formulations across markets

How does the clinical trial landscape look for oxytocin/Pitocin?

Current oxytocin product development in major markets is dominated by:

• Reformulations (form/route/device)
• Bioequivalence programs for generics
• Clinical protocol studies within obstetrics (often without testing “Pitocin” as a distinct active)

No robust, Pitocin-branded, late-stage (Phase 3) differentiation program is visible in public registries at a level that would support an investable “new entrant” narrative. The molecule is mature and widely studied historically, and contemporary trials tend to focus on dosing strategies, monitoring, and comparator regimens rather than creating proprietary clinical evidence tied to a single brand.

Actionable implication for R&D portfolios: near-term patentable upside is usually limited to formulation/device/IP around administration protocols, not on creating a new oxytocin efficacy and safety profile.

---

What is the current market structure for oxytocin/Pitocin?

Who drives demand?

Demand is driven by:

• Labor induction and augmentation rates
• Cesarean section prevalence (uterine tone management protocols intersect with obstetric workflows)
• Hospital formularies and procurement cycles

What determines pricing power?

Pricing is constrained by:

• Generic oxytocin availability
• Tender-based purchasing
• Multi-source contracting

Branded oxytocin typically retains market share where:

• Hospital systems maintain historical formularies
• Supply chain reliability and procurement preferences favor established suppliers
• Pricing differs by region due to regulatory approvals and tender dynamics

What are the main product competitive sets?

• Generic oxytocin injection (same active ingredient)
• Branded uterotonics in adjacent indications (market share is influenced by procurement bundles even if the active differs)

---

Clinical trial update: are there new efficacy or safety findings that move the market?

Do current trial results materially change standard of care?

Most contemporary research on oxytocin centers on:

• Dosing regimens
• Timing and titration protocols
• Monitoring strategies to reduce uterine hyperstimulation and fetal distress signals

These studies generally influence practice guidelines and hospital protocols rather than creating a brand-specific market shift for Pitocin.

Commercial relevance: guideline and protocol changes may shift relative use rates among uterotonics and dosing patterns, but they do not usually reprice the oxytocin category in a sustained way because competing products are substitutable at the active-ingredient level.

---

Market analysis: 2025 baseline and competitive dynamics

Category demand: key drivers

1. Hospital births volume in the served geography
2. Labor induction and augmentation adoption
3. Guideline-driven dosing and monitoring
4. Public and private procurement intensity

Competitive dynamics: key headwinds

• Generic price erosion is the dominant force.
• Switching risk remains high because the active ingredient is the same.
• Channel concentration (large group purchasing organizations) reduces brand-level differentiation.

Where can branded products still win?

• Contract retention with large hospital networks
• Supply continuity and bulk procurement relationships
• Region-specific regulatory and tender realities that delay complete generic switching

---

2025-2035 market projection for Pitocin/oxytocin

How is projection framed in this category?

For oxytocin, the practical forecast is that brand demand tracks:

• Total obstetric demand growth
• Share retention in branded tenders
• Price erosion due to generics
• Occasional country-level procurement shocks and supply issues

A projection for “Pitocin” specifically is sensitive to brand share and reimbursement behavior by country. Without brand-level unit sales data and without registry-linked brand development milestones, the only defensible approach is to project the oxytocin category and treat Pitocin as a portion of branded capture subject to ongoing generic pressure.

Base-case projection (oxytocin category; Pitocin as a branded slice)

• Volume: grows roughly in line with births volume and induction/augmentation adoption, with inflation-adjusted price pressure.
• Value: grows slower than volume due to price declines and procurement discounting.
• Market share: branded stabilizes if supply and contracting hold; otherwise continues drifting toward generics.

Operational forecast metrics to monitor (leading indicators):

• Tender outcomes in top hospital groups
• Switching rates from brand to generic oxytocin
• Hospital stockouts or supply interruptions (short-term demand capture)
• Changes in induction/augmentation guidelines that affect uterotonic titration frequency

---

Intellectual property and patent outlook

Is there a meaningful patent runway for Pitocin itself?

Oxytocin is not a new molecule. Patent protection for branded formulation IP, if any, is generally limited and largely expired in many jurisdictions for core active-ingredient use. In mature categories, future competitive advantage typically comes from:

• New delivery devices
• Stable formulations
• Supply chain and contracting strength
• Litigation outcomes around formulation manufacturing or packaging

Business implication: future value creation is less about excluding generics through strong active-ingredient IP and more about maintaining contracting share and operational reliability.

---

Key Takeaways

• Pitocin/oxytocin is mature and generic-substitutable, so clinical trial updates typically shift protocols rather than drive brand-level market repricing.
• Public clinical development evidence that would materially re-rate Pitocin-branded value is limited, with most modern work centering on dosing strategies and comparators in obstetrics rather than proprietary late-stage differentiation.
• Market value growth is structurally constrained by generic price erosion and tender contracting dynamics, with volume following obstetric demand and induction practices.
• Best-performing commercial levers for branded oxytocin are contracting, supply reliability, and formulary retention, not molecule innovation.
• 2025-2035 outlook favors steady volume with slow value growth, assuming continuing generic penetration.

---

FAQs

1. Is Pitocin undergoing Phase 3 trials that could shift standard of care?
   Most visible contemporary research in oxytocin is protocol- and regimen-focused rather than brand-distinct Phase 3 development that changes core indications.

2. What most affects Pitocin pricing in hospitals?
   Tender procurement, generic availability, and contracting power of large purchasing entities.

3. What will drive oxytocin category growth from 2025 to 2035?
   Birth volume trends and induction/augmentation adoption, with value limited by generic price pressure.

4. Where can a branded oxytocin product defend market share?
   Hospital formulary retention, supply continuity, and region-specific procurement inertia.

5. Do guideline changes translate into revenue upside for Pitocin?
   They can influence utilization patterns, but they usually do not lift category value substantially because substitutes are equivalent at the active-ingredient level.

---

References

[1] U.S. National Library of Medicine. ClinicalTrials.gov. https://clinicaltrials.gov/
[2] U.S. Food and Drug Administration. Drug approvals and labeling resources for oxytocin products. https://www.accessdata.fda.gov/
[3] European Medicines Agency. Human medicines information and assessments (oxytocin-related assessments where applicable). https://www.ema.europa.eu/
[4] WHO. Model list of essential medicines and uterotonic role context. https://www.who.int/